Prevalence of SARS-CoV-2 infection in patients presenting for intravitreal injection
- PDF / 315,059 Bytes
- 5 Pages / 595 x 842 pts (A4) Page_size
- 60 Downloads / 167 Views
Spektrum Augenheilkd. https://doi.org/10.1007/s00717-020-00473-3
Prevalence of SARS-CoV-2 infection in patients presenting for intravitreal injection Stephan Szegedi
· Wolfgang Huf
· Kata Miháltz
· Pia Veronika Vécsei-Marlovits
Received: 11 October 2020 / Accepted: 18 November 2020 © Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2020
Summary Aim Due to the coronavirus disease 2019 (COVID-19) pandemic, nosocomial transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of great concern to clinicians of all specialties. Currently there are no published data available on the prevalence of the infection in ophthalmology patients presenting for intravitreal injection (IVI). The purpose of this retrospective study was to estimate the prevalence of SARS-CoV-2 infection in patients presenting for IVI at our hospital. Methods Patients presenting for IVI in April 2020 at our hospital who had been screened for SARSCoV-2 infection using nasopharyngeal and oropharyngeal specimen for real-time reverse transcription polymerase chain reaction analysis were included in a retrospective study. To assess the representativity of this sample for IVI patients, characteristics were compared with patients presenting for IVI during March–April 2019. Results The study included 279 patients and 319 historic control patients. Of 277 valid test results, one SARS-CoV-2 positive patient was found, resulting in a carrier rate of 0.36% with a 95% Clopper–Pearson confidence interval of 0.01–1.99%. No differences in sex S. Szegedi () · K. Miháltz · P. V. Vécsei-Marlovits Department of Ophthalmology, Wiener Gesundheitsverbund, Hietzing Hospital, Wolkersbergenstraße 1, 1130 Vienna, Austria Karl Landsteiner Institute for Process Optimization and Quality Management in Cataract Surgery, Vienna, Austria [email protected] W. Huf Department of Laboratory Medicine, Wiener Gesundheitsverbund, Hietzing Hospital, Vienna, Austria Karl Landsteiner Institute for Clinical Risk Management, Vienna, Austria
K
(57.7% vs. 59.9% female, p = 0.650), age (77.63 ± 10.29 vs. 77.59 ± 10.94 years, p = 0.962), and region of residence were found between groups. Conclusion The study provides an estimate for the prevalence of SARS-CoV-2 infection in asymptomatic patients presenting for IVI. While these data may be used as a baseline, further research is needed to assess the development of SARS-CoV-2 prevalence in this patient group in order to support risk assessment and infection prevention strategies. Keywords Coronavirus · COVID-19 · Severe acute respiratory syndrome coronavirus 2 · Ophthalmology · Epidemiology
Prävalenz der SARS-CoV-2-Infektion bei Patienten mit intravitrealer Injektionstherapie Zusammenfassung Zielsetzung Durch die „coronavirus disease 2019“(COVID-19)-Pandemie ist die nosokomiale Übertragung des „severe acute respiratory syndrome coronavirus 2“ (SARS-CoV-2) von großer Bedeutung für Kliniker aller Fachrichtungen. Derzeit liegen keine Daten zur Prävalenz der Infektion bei ophthalmologischen Patien
Data Loading...
